Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?

Abstract

Letter to the EditorReply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?Júlio César Rocha, Conceição Calhau, and Anita MacDonaldJúlio César RochaNutrition & Metabolism, Nova Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, PortugalCenter for Health Technology and Services Research (CINTESIS), Porto, Portugal, Conceição CalhauNutrition & Metabolism, Nova Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, PortugalCenter for Health Technology and Services Research (CINTESIS), Porto, Portugal, and Anita MacDonaldDepartment of Dietetics, Birmingham Children’s Hospital, Birmingham, United KingdomPublished Online:01 Jun 2020https://doi.org/10.1152/ajpendo.00195.2020MoreSectionsPDF (56 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat to the editor: In his outstanding article, Jakovac (7) highlighted the relevance of vitamin D in coronavirus disease (COVID-19) context. In fact, this seems an important metabolic explanation for the higher vulnerability for severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the patients with obesity and hypertension or older patients. There are no published intervention studies to prove that vitamin D supplementation could help with COVID-19 outcomes. However, our group specializing in phenylketonuria (PKU; McKusick #261600) are unaware of any reported deaths from COVID-19 in this patient group. Could it be that patients with PKU are spared from COVID-19 severe outcomes? A proof of concept that vitamin D status could effectively help infected individuals with the new coronavirus might be fostered from this observation.In fact, for many patients with PKU, a phenylalanine-restricted diet remains the only management strategy, despite emerging pharmacological treatments. It is established that stringent dietary treatment accomplishes near-normal outcomes (14). Dietary management involves a controlled phenylalanine intake, supplemented with a low phenylalanine protein substitute, usually containing micronutrients (12). Initially, nutritional requirements were not fully understood, and unpalatable medical formulas without rigorous supplementation led to nutritional deficiencies (10). In recent years, the quality of dietary treatment has considerably improved, protein substitutes are fortified with micronutrients to meet requirements, and there are few reports of micronutrient inadequacy in PKU (8). Balanced nutrition is required for optimal cell function with vitamins A, B6, B12, C, D, E, folate, trace elements, and essential fatty acids important and complementary in supporting the immune system (1).Although vitamin D deficiency is common in the general population, several recent studies reported good or improved vitamin D status in patients with PKU, dependent on the amount of protein substitute being consumed. A patient, taking 60 g/day protein equivalent from protein substitute will receive around 13 to 30 µg/day of vitamin D compared with a requirement varying between 10 to 15 µg/day for adults (3, 15). In the United Kingdom, Daly et al. (2) reported median 25-hydroxy-vitamin D levels above 80 nmol/L in 50 PKU diet-treated patients aged 5 to 16 yr. At the end of 1 yr intervention, no patient had a vitamin D concentration of ≤50 nmol/L. Also, in adults with PKU, the vitamin D intake was significantly higher in diet-adherent compared with nonadherent patients (25.8 ± 8.96 vs. 4.16 ± 5.31 μg/day, respectively; P < 0.001) (6). Thiele et al. (16) showed in patients with PKU that vitamin D intake decreased to less than requirements when protein substitute intake was lowered as a consequence of pharmacological treatment. A recent, retrospective study from early treated adults with PKU patients from 17 European centers highlighted a low number (n = 32 of 173) of patients with low vitamin D status (25-OH vitamin D <50 nmol/L) (9). Experience from Portugal comparing a group of patients with PKU with healthy controls showed vitamin D inadequacy was more prevalent in the control group (13).Although there is no direct evidence that vitamin D will prevent or treat COVID-19, vitamin D may help (5). Data from the University of Turin, Italy, indicated a high prevalence of hypovitaminosis D in hospitalized patients with COVID-19 (4). In PKU, associated with the nutrient supplementation in protein substitutes, it is possible that satisfactory vitamin D status offers protection against COVID-19. This, of course, is speculation, and COVID-19 incidence in patients with PKU within and between countries is not reported. To understand if nutritional status may influence acute respiratory infection rate in COVID-19, it seems important to study the occurrence of COVID-19 in adolescent and adult patients with PKU and compare outcome with their treatment status. In addition, individual susceptibility to vitamin D deficiency and dose response of supplementation strategies should be based on assessing single nucleotide polymorphisms (SNPs) in vitamin D metabolism (11, 17).DISCLOSURESJ. C. Rocha is member of the European Nutrition Expert Panel (Biomarin) and of the advisory boards of Applied Pharma Research and Nutricia. He has received speaker’s fees from Applied Pharma Research, Merck Serono, BioMarin, Nutricia, Vitaflo, Cambrooke, PIAM, and Lifediet. A. MacDonald has received research funding and honoraria from Nutricia, Vitaflo International and Merck Serono. She is a member of the European Nutritionist Expert Panel (Biomarin), a member of Sapropterin Advisory Board (Biomarin), a member of the advisory board entitled ELEMENT (Danone-Nutricia), and a member of an advisory board for Arla and Applied Pharma Research. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.AUTHOR CONTRIBUTIONSJ.C.R. drafted manuscript; J.C.R., C.C., and A.M. edited and revised manuscript; J.C.R., C.C., and A.M. approved final version of manuscript.REFERENCES1. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 12: E1181, 2020. doi:10.3390/nu12041181. Crossref | PubMed | Google Scholar2. Daly A, Evans S, Chahal S, Santra S, Pinto A, Jackson R, Gingell C, Rocha J, Van Spronsen FJ, MacDonald A. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU. Orphanet J Rare Dis 14: 44, 2019. doi:10.1186/s13023-019-1011-y. Crossref | PubMed | ISI | Google Scholar3. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). Dietary reference values for vitamin D. EFSA J 14: 4547, 2016. doi:10.2903/j.efsa.2016.4547.Crossref | Google Scholar4. Isaia G. Possibile ruolo preventivo e terapeutico della vitamina D nella gestione della pandemia da COVID-19. https://www.unitonews.it/storage/2515/8522/3585/Ipovitaminosi_D_e_Coronavirus_25_marzo_2020.pdf [Accessed 21 May 2020].Google Scholar5. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths. Nutrients 12: E988, 2020. doi:10.3390/nu12040988. Crossref | PubMed | ISI | Google Scholar6. Green B, Browne R, Firman S, Hill M, Rahman Y, Kaalund Hansen K, Adam S, Skeath R, Hallam P, Herlihy I, Jenkinson F, Nicol C, Adams S, Gaff L, Donald S, Dawson C, Robertson L, Fitzachary C, Chan H, Slabbert A, Dunlop C, Cozens A, Newby C, Bittle V, Hubbard G, Stratton R. Nutritional and metabolic characteristics of UK adult phenylketonuria patients with varying dietary adherence. Nutrients 11: 2459, 2019. doi:10.3390/nu11102459. Crossref | PubMed | ISI | Google Scholar7. Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab 318: E589, 2020. doi:10.1152/ajpendo.00138.2020. Link | ISI | Google Scholar8. Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, Ozel HG, Goyens P, Feillet F. Main issues in micronutrient supplementation in phenylketonuria. Mol Genet Metab 110, Suppl: S1–S5, 2013. doi:10.1016/j.ymgme.2013.08.008. Crossref | PubMed | ISI | Google Scholar9. Lubout CMA, Arrieta Blanco F, Bartosiewicz K, Feillet F, Gizewska M, Hollak C, van der Lee JH, Maillot F, Stepien KM, Wagenmakers MAEM, Welsink-Karssies MM, van Spronsen FJ, Bosch AM. Bone mineral density is within normal range in most adult phenylketonuria patients. J Inherit Metab Dis 43: 251–258, 2020. doi:10.1002/jimd.12177. Crossref | PubMed | ISI | Google Scholar10. Pena MJ, de Almeida MF, van Dam E, Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Robert M, Rocha JC. Protein substitutes for phenylketonuria in Europe: access and nutritional composition. Eur J Clin Nutr 70: 785–789, 2016. doi:10.1038/ejcn.2016.54. Crossref | PubMed | ISI | Google Scholar11. Revez JA, Lin T, Qiao Z, Xue A, Holtz Y, Zhu Z, Zeng J, Wang H, Sidorenko J, Kemper KE, Vinkhuyzen AAE, Frater J, Eyles D, Burne THJ, Mitchell B, Martin NG, Zhu G, Visscher PM, Yang J, Wray NR, McGrath JJ. Genome-wide association study identifies 143 loci associated with 25 hydroxyvitamin D concentration. Nat Commun 11: 1647, 2020. doi:10.1038/s41467-020-15421-7. Crossref | PubMed | ISI | Google Scholar12. Rocha JC, Macdonald A. Treatment options and dietary supplements for patients with phenylketonuria. Expert Opin Orphan Drugs 6: 667–681, 2018. doi:10.1080/21678707.2018.1536541.Crossref | ISI | Google Scholar13. Rocha JC, Silva N, van Spronsen FJ, Almeida MF, Borges N, Guimarães JT. Serum vitamin D levels in patients with phenylketonuria. J Inherit Metab Dis 38: S91–S92, 2015.Google Scholar14. Romani C, Manti F, Nardecchia F, Valentini F, Fallarino N, Carducci C, De Leo S, MacDonald A, Palermo L, Leuzzi V. Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels. Orphanet J Rare Dis 14: 273, 2019. doi:10.1186/s13023-019-1225-z. Crossref | PubMed | ISI | Google Scholar15. The Scientific Advisory Committee on Nutrition (SACN). SACN vitamin D and health report. [Online]. https://www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition [2 May 2020].Google Scholar16. Thiele AG, Rohde C, Mütze U, Arelin M, Ceglarek U, Thiery J, Baerwald C, Kiess W, Beblo S. The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: Effects on metabolic control, nutritional habits and nutrient supply. Mol Genet Metab Rep 4: 62–67, 2015. doi:10.1016/j.ymgmr.2015.07.002. Crossref | PubMed | ISI | Google Scholar17. Zhang M, Zhao LJ, Zhou Y, Badr R, Watson P, Ye A, Zhou B, Zhang J, Deng HW, Recker RR, Lappe JM. SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial. Sci Rep 7: 40593, 2017. doi:10.1038/srep40593. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESCorrespondence: J. C. Rocha ([email protected]unl.pt). Download PDF Previous Back to Top FiguresReferencesRelatedInformation Related ArticlesCOVID-19 and vitamin D—Is there a link and an opportunity for intervention? 16 Apr 2020American Journal of Physiology-Endocrinology and MetabolismReply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness? 13 Aug 2020American Journal of Physiology-Endocrinology and MetabolismCited ByPhenylalanine and COVID-19: Tracking disease severity markersInternational Immunopharmacology, Vol. 101Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?Andrzej T. Slominski, Radomir M. Slominski, Paul A. Goepfert, Tae-Kang Kim, Michael F. Holick, Anton M. Jetten, and Chander Raman13 August 2020 | American Journal of Physiology-Endocrinology and Metabolism, Vol. 319, No. 2 More from this issue > Volume 318Issue 6June 2020Pages E890-E891 Copyright & PermissionsCopyright © 2020 the American Physiological Societyhttps://doi.org/10.1152/ajpendo.00195.2020PubMed32479158History Received 6 May 2020 Accepted 11 May 2020 Published online 1 June 2020 Published in print 1 June 2020 KeywordsCOVID-19phenylketonuriavitamin D Metrics